Integrin alpha-5 silencing leads to myofibroblastic differentiation in IPF-derived human lung fibroblasts.
fibroblasts
idiopathic pulmonary fibrosis
integrin α5
integrin α8
siRNA
Journal
Therapeutic advances in chronic disease
ISSN: 2040-6223
Titre abrégé: Ther Adv Chronic Dis
Pays: United States
ID NLM: 101532140
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
03
2020
accepted:
21
05
2020
entrez:
9
7
2020
pubmed:
9
7
2020
medline:
9
7
2020
Statut:
epublish
Résumé
The term 'fibroblast' covers a heterogeneous cell population in idiopathic pulmonary fibrosis (IPF). The fibroblasts are considered as main effector cells, because they promote disease progression by releasing exaggerated amounts of extracellular matrix proteins and modifying cell microenvironment. As IPF-derived human lung fibroblasts (IPF-HLFs) were shown to express higher levels of integrin alpha-5 (ITGA5) than normal derived HLFs (N-HLFs), we explored the importance of ITGA5 to IPF progression. IPF-HLF and N-HLF primary cultures were established. ITGA5 was silenced by specific small interfering RNA (siRNA)s and its effects on cell phenotype (e.g. cell number, size, cell death, migration) and gene expression (e.g. RNA sequencing, quantitative polymerase chain reaction [qPCR], western blot and immunofluorescence) were tested. Specific integrin expression was evaluated in IPF patient formalin-fixed paraffin embedded sections by immunohistochemistry (IHC). ITGA5-silencing resulted in reduced IPF-HLF proliferation rates and cell migration ( ITGA5 expression facilitates a more aggressive proliferative phenotype. Downregulation of this integrin results in myofibroblastic differentiation, which is accompanied by elevated ITGA8. Specific targeting could present a therapeutic benefit.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
The term 'fibroblast' covers a heterogeneous cell population in idiopathic pulmonary fibrosis (IPF). The fibroblasts are considered as main effector cells, because they promote disease progression by releasing exaggerated amounts of extracellular matrix proteins and modifying cell microenvironment. As IPF-derived human lung fibroblasts (IPF-HLFs) were shown to express higher levels of integrin alpha-5 (ITGA5) than normal derived HLFs (N-HLFs), we explored the importance of ITGA5 to IPF progression.
METHODS
METHODS
IPF-HLF and N-HLF primary cultures were established. ITGA5 was silenced by specific small interfering RNA (siRNA)s and its effects on cell phenotype (e.g. cell number, size, cell death, migration) and gene expression (e.g. RNA sequencing, quantitative polymerase chain reaction [qPCR], western blot and immunofluorescence) were tested. Specific integrin expression was evaluated in IPF patient formalin-fixed paraffin embedded sections by immunohistochemistry (IHC).
RESULTS
RESULTS
ITGA5-silencing resulted in reduced IPF-HLF proliferation rates and cell migration (
CONCLUSIONS
CONCLUSIONS
ITGA5 expression facilitates a more aggressive proliferative phenotype. Downregulation of this integrin results in myofibroblastic differentiation, which is accompanied by elevated ITGA8. Specific targeting could present a therapeutic benefit.
Identifiants
pubmed: 32637060
doi: 10.1177/2040622320936023
pii: 10.1177_2040622320936023
pmc: PMC7315658
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2040622320936023Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Proc Am Thorac Soc. 2006 Jul;3(5):413-7
pubmed: 16799084
J Cell Biol. 1989 Aug;109(2):863-75
pubmed: 2527241
J Pathol. 2008 Jan;214(2):199-210
pubmed: 18161745
Am J Physiol Renal Physiol. 2007 Feb;292(2):F567-76
pubmed: 17018844
F1000Res. 2016 Apr 26;5:
pubmed: 27158462
Am J Respir Crit Care Med. 2012 Nov 1;186(9):866-76
pubmed: 22936357
EMBO Rep. 2010 Feb;11(2):97-105
pubmed: 20075988
Am J Pathol. 2000 Jun;156(6):1927-35
pubmed: 10854216
Mol Carcinog. 2017 Jan;56(1):62-74
pubmed: 26859229
Am J Physiol Cell Physiol. 2001 Nov;281(5):C1457-67
pubmed: 11600408
PLoS One. 2008 Sep 16;3(9):e3220
pubmed: 18795102
Nature. 2013 Dec 12;504(7479):277-281
pubmed: 24336287
Elife. 2017 Jan 31;6:
pubmed: 28139197
PLoS One. 2018 May 29;13(5):e0197937
pubmed: 29813125
Am J Pathol. 2012 Apr;180(4):1340-55
pubmed: 22387320
Stem Cells Transl Med. 2014 Nov;3(11):1342-53
pubmed: 25273539
Ann Am Thorac Soc. 2016 Dec;13 Suppl 5:S417-S421
pubmed: 28005427
Respir Res. 2017 Jun 19;18(1):122
pubmed: 28629363
Biochem Biophys Res Commun. 2005 Jun 3;331(2):428-34
pubmed: 15850777
Chest. 2007 Oct;132(4):1311-21
pubmed: 17934117
Am J Pathol. 2006 Feb;168(2):499-510
pubmed: 16436664
Nat Cell Biol. 2000 Jan;2(1):E13-4
pubmed: 10620816
J Biol Chem. 2008 May 9;283(19):12898-908
pubmed: 18353785
Am J Respir Crit Care Med. 2014 May 15;189(10):1161-72
pubmed: 24641682
Wound Repair Regen. 2004 Jul-Aug;12(4):461-70
pubmed: 15260812
Mol Cell Proteomics. 2004 May;3(5):466-77
pubmed: 14766930
Exp Cell Res. 2015 Jul 15;335(2):187-96
pubmed: 26022665
J Cell Sci. 1995 Feb;108 ( Pt 2):537-44
pubmed: 7768999
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
J Cell Biol. 2005 Aug 29;170(5):793-802
pubmed: 16129786
Adv Drug Deliv Rev. 2018 Apr;129:37-53
pubmed: 29414674
J Mol Cell Cardiol. 2004 Mar;36(3):343-53
pubmed: 15010273
J Clin Invest. 2014 Jul;124(7):2921-34
pubmed: 24937432
PLoS One. 2018 Nov 1;13(11):e0206786
pubmed: 30383875
Proc Am Thorac Soc. 2012 Jul;9(3):137-47
pubmed: 22802288
Matrix Biol. 2004 Oct;23(6):333-40
pubmed: 15533754
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Int J Biochem Cell Biol. 2001 Jul;33(7):723-34
pubmed: 11390280
Am J Physiol Lung Cell Mol Physiol. 2019 Jun 1;316(6):L1025-L1034
pubmed: 30810067
Adv Drug Deliv Rev. 2007 Nov 10;59(13):1293-8
pubmed: 17825946
Front Immunol. 2018 Nov 13;9:2452
pubmed: 30483246
Curr Opin Cell Biol. 2005 Oct;17(5):524-32
pubmed: 16112853
Nephrol Dial Transplant. 2002;17 Suppl 9:71-2
pubmed: 12386295
Drug Discov Today. 2013 Mar;18(5-6):240-9
pubmed: 23073387
Science. 2015 Apr 17;348(6232):aaa2151
pubmed: 25883361